PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
暂无分享，去创建一个
M. Stockler | I. Davis | M. Hofman | S. Lee | A. Iravani | S. Sandhu | A. Joshua | A. Azad | R. Francis | A. Martin | L. Emmett | Scott G. Williams | A. Scott | A. Zhang | J. Buteau | M. McJannett | M. Mcjannett | Andrew M. Scott | S. Williams